From the Division of Family Planning, Department of Obstetrics and Gynecology (D.K.T., A.G., R.G.S., J.E.K., C.D.S., L.M.G., J.N.S.), and the Division of Epidemiology, Department of Internal Medicine (G.J.S.), University of Utah, Salt Lake City.
N Engl J Med. 2021 Jan 28;384(4):335-344. doi: 10.1056/NEJMoa2022141.
In the United States, more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term contraception. Currently, clinicians offer only copper IUDs for emergency contraception because data are lacking on the efficacy of the levonorgestrel IUD for this purpose.
This randomized noninferiority trial, in which participants were unaware of the group assignments, was conducted at six clinics in Utah and included women who sought emergency contraception after at least one episode of unprotected intercourse within 5 days before presentation and agreed to placement of an IUD. We randomly assigned participants in a 1:1 ratio to receive a levonorgestrel 52-mg IUD or a copper T380A IUD. The primary outcome was a positive urine pregnancy test 1 month after IUD insertion. When a 1-month urine pregnancy test was unavailable, we used survey and health record data to determine pregnancy status. The prespecified noninferiority margin was 2.5 percentage points.
Among the 355 participants randomly assigned to receive levonorgestrel IUDs and 356 assigned to receive copper IUDs, 317 and 321, respectively, received the interventions and provided 1-month outcome data. Of these, 290 in the levonorgestrel group and 300 in the copper IUD group had a 1-month urine pregnancy test. In the modified intention-to-treat and per-protocol analyses, pregnancy rates were 1 in 317 (0.3%; 95% confidence interval [CI], 0.01 to 1.7) in the levonorgestrel group and 0 in 321 (0%; 95% CI, 0 to 1.1) in the copper IUD group; the between-group absolute difference in both analyses was 0.3 percentage points (95% CI, -0.9 to 1.8), consistent with the noninferiority of the levonorgestrel IUD to the copper IUD. Adverse events resulting in participants seeking medical care in the first month after IUD placement occurred in 5.2% of participants in the levonorgestrel IUD group and 4.9% of those in the copper IUD group.
The levonorgestrel IUD was noninferior to the copper IUD for emergency contraception. (Supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; ClinicalTrials.gov number, NCT02175030.).
在美国,选择长效避孕的宫内节育器(IUD)用户中,使用左炔诺孕酮 IUD 的多于使用铜 IUD 的。目前,由于缺乏左炔诺孕酮 IUD 用于紧急避孕的有效性数据,临床医生仅提供铜 IUD 用于紧急避孕。
这是一项随机非劣效性试验,参与者对分组情况不知情,在犹他州的六家诊所进行,纳入了在就诊前至少有一次无保护性行为且在 5 天内,并同意放置 IUD 的寻求紧急避孕的女性。我们以 1:1 的比例随机分配参与者接受左炔诺孕酮 52mg IUD 或铜 T380A IUD。主要结局为放置 IUD 1 个月后尿妊娠试验阳性。如果无法进行 1 个月尿妊娠试验,我们将使用调查和健康记录数据来确定妊娠状态。预设的非劣效性边界为 2.5 个百分点。
在随机分配至接受左炔诺孕酮 IUD 组的 355 名参与者和接受铜 IUD 组的 356 名参与者中,分别有 317 名和 321 名参与者接受了干预措施并提供了 1 个月的结局数据。其中,左炔诺孕酮组有 290 名和铜 IUD 组有 300 名参与者进行了 1 个月尿妊娠试验。在改良意向治疗和方案分析中,左炔诺孕酮组的妊娠率为 1/317(0.3%;95%置信区间 [CI],0.01 至 1.7),铜 IUD 组为 0/321(0%;95% CI,0 至 1.1);两组之间的绝对差异在这两种分析中均为 0.3 个百分点(95% CI,-0.9 至 1.8),与左炔诺孕酮 IUD 不劣于铜 IUD 一致。放置 IUD 后 1 个月内因不良事件而寻求医疗护理的参与者在左炔诺孕酮 IUD 组中占 5.2%,在铜 IUD 组中占 4.9%。
左炔诺孕酮 IUD 用于紧急避孕不劣于铜 IUD。(由 Eunice Kennedy Shriver 国立儿童健康与人类发育研究所和其他机构支持;ClinicalTrials.gov 编号,NCT02175030)。